Arch Biopartners Engages Nucro-Technics To Complete Toxicology Studies To Support Investigational New Drug Application For Metablok
TORONTO, May 22, 2018 (GLOBE NEWSWIRE) -- Arch Biopartners, Inc., (Arch or the Company) (TSX Venture:ARCH) (OTCQB:ACHFF) a portfolio-based biotechnology company, today announced it has engaged Nucro-Technics in Scarborough, Ontario to complete the preclinical toxicology and pharmacology studies to support an Investigational New Drug (IND) application for Metablok, the Company’s drug candidate for preventing acute kidney injury.
Specifically, Nucro-Technics will be performing the good laboratory practice (GLP) toxicology and pharmacology studies previously confirmed by the U.S. Food and Drug Administration (FDA) during the pre-IND meeting with the Company on April 18, 2018.
Arch is preparing an IND application and a Phase I human trial to evaluate Metablok’s safety and pharmacokinetic profile in advance of future clinical trials to test its efficacy in treating or preventing cardiac surgery-associated acute kidney injury.
Nucro-Technics looks forward to continuing to advance Arch Biopartners drug candidate Metablok through to clinical stages. “We are pleased to support Arch Biopartners upcoming IND application for Metablok by performing the required toxicology and pharmacology studies,” said John C. Fanaras, President of Nucro-Technics.
About Metablok (LSALT peptide)
Metablok (renamed “LSALT peptide” in Arch communications with FDA) is a novel peptide drug candidate in the Arch development pipeline and a potential treatment for the following highly problematic indications: (i) inflammation, (ii) sepsis and (iii) cancer metastasis.
Inflammation and Acute Kidney Injury:
Inflammation is a localized physical condition that involves the activation of the immune system in response to infection, tissue injury, or autoimmunity. Inflammation is involved in the pathogenesis of many diseases and plays a significant role in acute kidney injury. Acute kidney injury due to ischemia/reperfusion occurs in up to 30% of patients undergoing cardiovascular surgeries.
Nucro-Technics is Canada’s largest privately held, single-site pharmaceutical contract service organization. Specialized in pre-clinical research and development, Nucro-Technics has been in business for over 45 years servicing its clients in a professional and timely manner. The multidisciplinary services offered on-site allow the organization to function as a single-point-of contact for companies that need to fulfill IND testing requirements to bring their products through to the next phase of drug development.
Nucro-Technics is in compliance with both FDA and Health Canada regulations, and has been accredited as a GLP facility by the Standards Council of Canada to the OECD standard. As such, Nucro-Technics has a long history of providing GLP and GMP-compliant contracted research and development services to a wide array of pharmaceutical and biotech firms, both large and small.
For additional information on Nucro-Technics, the single destination for a company’s contract research and support needs, please visit www.nucro-technics.com or call (416) 438-6727.
About Arch Biopartners
Arch Biopartners Inc. is focused on the development of innovative technologies that have the potential to make a significant medical or commercial impact.Arch has established a diverse portfolio that includes AB569, a potential new treatment for antibiotic resistant bacterial infections in the lung, urinary tract or wounds; Metablok (LSALT peptide), a potential treatment for inflammation, sepsis and cancer metastasis; and, ‘Borg’ peptide coatings that increase corrosion resistance and decrease bacterial biofilm on various medical grade metals and plastics.
For more information on Arch Biopartners, its technologies and other public documents Arch has filed on SEDAR, please visit www.archbiopartners.com
The Company has 57,902,429 common shares outstanding as of May 22, 2018.
All statements, other than statements of historical fact, in this news release are forward looking statements that involve various risks and uncertainties, including, without limitation, statements regarding the future plans and objectives of the Company. There can be no assurance that such statements will prove to be accurate. Actual results and future events could differ materially from those anticipated in such statements. These and all subsequent written and oral forward-looking statements are based on the estimates and opinions of management on the dates they are made and are expressly qualified in their entirety by this notice. The Company assumes no obligation to update forward-looking statements should circumstances or management’s estimates or opinions change.
Neither TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.